{"nctId":"NCT01405508","briefTitle":"Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy","startDateStruct":{"date":"2011-08"},"conditions":["Epilepsy"],"count":105,"armGroups":[{"label":"Placebo tablets / Brivaracetam bolus","type":"EXPERIMENTAL","interventionNames":["Drug: Brivaracetam bolus","Other: Placebo"]},{"label":"Brivaracetam (BRV) tablets / BRV bolus","type":"EXPERIMENTAL","interventionNames":["Drug: Brivaracetam tablets","Drug: Brivaracetam bolus"]},{"label":"Placebo tablets / Brivaracetam infusion","type":"EXPERIMENTAL","interventionNames":["Drug: Brivaracetam infusion","Other: Placebo"]},{"label":"Brivaracetam (BRV) tablets / BRV infusion","type":"EXPERIMENTAL","interventionNames":["Drug: Brivaracetam tablets","Drug: Brivaracetam infusion"]}],"interventions":[{"name":"Brivaracetam tablets","otherNames":[]},{"name":"Brivaracetam bolus","otherNames":[]},{"name":"Brivaracetam infusion","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* An Institutional Review Board/Independent Ethics Committee (IRB/IEC) approved written Informed Consent form signed and dated by the subject or by parent(s) or legal representative\n* Subjects from 16 to 70 years\n* Subjects with a body weight of \\>/= 40 kg\n* Female subjects without childbearing potential or female subjects with childbearing potential if they use a medically accepted contraceptive method\n* Subject/legal representative considered as reliable and capable of adhering to the protocol\n* Subjects with well-characterized focal or generalized epilepsy or epileptic syndrome\n* Subjects with a history of partial-onset seizures whether or not secondarily generalized or primary generalized seizures\n* Subjects being uncontrolled while treated with 1 to 2 permitted concomitant antiepileptic drugs (AEDs)\n* Permitted concomitant antiepileptic drugs (AEDs) and vagus nerve stimulation (VNS) being stable and at optimal dosage for the subject from at least 1 month before Visit 1 and expected to be kept stable during the Run-In and Evaluation Periods\n\nExclusion Criteria:\n\n* Mentally impaired subjects unable to understand the study purpose\n* History or presence of status epilepticus during 1 year preceding Visit 1 or Baseline\n* Subjects on felbamate with less than 18 months continuous exposure before Visit 1\n* Subjects currently on vigabatrin\n* Subject taking any drug with possible relevant central nervous system effects except is stable from at least 1 month before Visit 1 and expected to be kept stable during the trial\n* Subjects taking any drug that may significantly influence the metabolism of Brivaracetam (BRV) except if the dose has been kept stable at least 1 month before Visit 1, and is expected to be kept stable during the trial\n* History of cerebrovascular accident in the last 6 months\n* Subjects suffering from severe cardiovascular disease or peripheral vascular disease\n* Presence of any sign suggesting rapidly progressing brain disorder or brain tumor\n* Any clinical conditions which impair reliable participation in the study or necessitate the use of medication not allowed by protocol\n* Presence of a terminal illness\n* Presence of a serious infection\n* Subjects with a history of sever adverse hematologic reaction to any drug\n* Subjects suffering from severe disturbance of hemostasis\n* Impaired hepatic function: alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT) values of more than 3 times the upper limit of the reference range\n* Subjects having clinically significant deviations from reference range values for laboratory parameters: creatinine clearance calculated \\< 50 ml / min, platelets \\< 100,000 / µL, or neutrophil cells \\< 1,800 / µL\n* Clinically significant electrocardiogram (ECG) abnormalities according to the Investigator\n* History of suicide attempt\n* In the Investigator's medical judgment, any current suicidal ideation or other serious psychiatric disorders requiring of having required hospitalization or medication\n* Known allergic reaction or intolerance to pyrrolidone derivatives and / or investigational product excipients\n* Known multiple drug allergies or severe drug allergy\n* Pregnant or lactating women\n* Known alcohol or drug addiction or abuse within the last 2 years\n* Subject institutionalized under judicial decision\n* Problems of venous accessibility\n* Subject taking part in another clinical / pharmacological study in the month preceding enrollment (Visit 1)\n* Investigators, coinvestigators, their spouses or children, or any study collaborators\n* Subjects previously treated with Brivaracetam (BRV)\n* Subject previously screened within this study","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With at Least One Treatment-emergent Adverse Event During the Study (Maximum 40 Days)","description":"An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"21","spread":null},{"groupId":"OG003","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Withdrew Due to a Treatment-emergent Adverse Event During the Study (Maximum 40 Days)","description":"An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With at Least One Injection-related Treatment-emergent Adverse Event (TEAE) During the Evaluation Period.","description":"An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":["Somnolence","Dizziness","Headache","Fatigue","Vertigo"]}}}